These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
471 related articles for article (PubMed ID: 29452419)
21. A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model. Towner RA; Ihnat M; Saunders D; Bastian A; Smith N; Pavana RK; Gangjee A BMC Cancer; 2015 Jul; 15():522. PubMed ID: 26177924 [TBL] [Abstract][Full Text] [Related]
22. Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors. Sardi I; Cetica V; Massimino M; Buccoliero AM; Giunti L; Genitori L; Aricò M Oncol Rep; 2009 Oct; 22(4):773-9. PubMed ID: 19724855 [TBL] [Abstract][Full Text] [Related]
23. Gene expression profiles predicting the response to IFN-β and a combination of temozolomide and IFN-β in malignant gliomas. Yoshino A; Tashiro S; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Sano E; Tsumoto K Int J Oncol; 2011 Sep; 39(3):529-42. PubMed ID: 21805051 [TBL] [Abstract][Full Text] [Related]
24. Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. Chamberlain MC Expert Rev Neurother; 2010 Oct; 10(10):1537-44. PubMed ID: 20925470 [TBL] [Abstract][Full Text] [Related]
25. Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics. Izquierdo C; Alentorn A; Idbaih A; Simó M; Kaloshi G; Ricard D; Barritault M; Meyronet D; Bruna J; Honnorat J; Delattre JY; Ducray F J Neurooncol; 2018 Feb; 136(3):533-539. PubMed ID: 29143276 [TBL] [Abstract][Full Text] [Related]
26. GINS2 regulates temozolomide chemosensitivity via the EGR1/ECT2 axis in gliomas. He H; Liang L; Jiang S; Liu Y; Huang J; Sun X; Li Y; Jiang Y; Cong L Cell Death Dis; 2024 Mar; 15(3):205. PubMed ID: 38467631 [TBL] [Abstract][Full Text] [Related]
27. Clinical and Molecular Recursive Partitioning Analysis of High-grade Glioma Treated With IMRT. Sutera P; Kalash R; Flickinger J; Engh J; Heron DE Am J Clin Oncol; 2019 Jan; 42(1):27-35. PubMed ID: 29912004 [TBL] [Abstract][Full Text] [Related]
28. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Kaloshi G; Benouaich-Amiel A; Diakite F; Taillibert S; Lejeune J; Laigle-Donadey F; Renard MA; Iraqi W; Idbaih A; Paris S; Capelle L; Duffau H; Cornu P; Simon JM; Mokhtari K; Polivka M; Omuro A; Carpentier A; Sanson M; Delattre JY; Hoang-Xuan K Neurology; 2007 May; 68(21):1831-6. PubMed ID: 17515545 [TBL] [Abstract][Full Text] [Related]
29. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status. Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314 [TBL] [Abstract][Full Text] [Related]
35. A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication. Wei J; Yang G; Hao X; Gu D; Tan Y; Wang X; Dong D; Zhang S; Wang L; Zhang H; Tian J Eur Radiol; 2019 Feb; 29(2):877-888. PubMed ID: 30039219 [TBL] [Abstract][Full Text] [Related]
36. Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation. Schiff D Cancer Invest; 2007 Dec; 25(8):776-84. PubMed ID: 17952745 [TBL] [Abstract][Full Text] [Related]
37. The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients' survival. Fogli A; Chautard E; Vaurs-Barrière C; Pereira B; Müller-Barthélémy M; Court F; Biau J; Pinto AA; Kémény JL; Khalil T; Karayan-Tapon L; Verrelle P; Costa BM; Arnaud P Carcinogenesis; 2016 Feb; 37(2):169-176. PubMed ID: 26717998 [TBL] [Abstract][Full Text] [Related]
38. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. Wahl M; Phillips JJ; Molinaro AM; Lin Y; Perry A; Haas-Kogan DA; Costello JF; Dayal M; Butowski N; Clarke JL; Prados M; Nelson S; Berger MS; Chang SM Neuro Oncol; 2017 Feb; 19(2):242-251. PubMed ID: 27571885 [TBL] [Abstract][Full Text] [Related]
39. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Kesari S; Schiff D; Drappatz J; LaFrankie D; Doherty L; Macklin EA; Muzikansky A; Santagata S; Ligon KL; Norden AD; Ciampa A; Bradshaw J; Levy B; Radakovic G; Ramakrishna N; Black PM; Wen PY Clin Cancer Res; 2009 Jan; 15(1):330-7. PubMed ID: 19118062 [TBL] [Abstract][Full Text] [Related]
40. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]